Antitrust Litigation

Wexler Wallace has been a leader in private antitrust enforcement, bringing a wide variety of class action cases to state and federal courts. Wexler Wallace’s cases have addressed antitrust violations in the pharmaceutical, entertainment, service rental, lumber, energy, and electronic products industries, among others.

“[Antitrust laws] are as important to the preservation of economic freedom and our free-enterprise system as the Bill of Rights is to the protection of our fundamental personal freedoms.” U.S. v. Topco Associates, Inc., 405 U.S. 596, 610 (1972).

Unfortunately, individuals and businesses sometimes violate the rules of our market-based system to artificially inflate prices.  Antitrust conduct can take the form of illegally-maintained monopolies, price fixing, the exchange of competitive information, patent abuse, and other forms of unfair competition.

If you believe you or your business may have been victimized by anticompetitive conduct, please contact us.

Antitrust Litigation cases

Celebrex Antitrust Litigation
In July 2014, Wexler Wallace LLP filed a class action case on behalf of end-payors (i.e., consumers and third-party payors, such as insurers and health benefit welfare funds) alleging that defendants (Pfizer and its subsidiaries) unlawfully suppressed generic competition for the blockbuster drug Celebrex. The United States Court of Appeals ruled in 2008 that the patent was invalid and not patentably distinct from previous Pfizer patents that covered the celecoxib compound – the active ingredient in Celebrex used to treat inflammation-related disorders. Read more.

Niaspan Antitrust Litigation
Wexler Wallace LLP is one of the Co-Lead Counsel for the plaintiffs in an antitrust class action case against AbbVie Inc. and Teva Pharmaceuticals USA Inc. (and their related companies) on behalf of End-Payors who purchased the cholesterol drug Niaspan. The plaintiffs allege that AbbVie and Teva (and their predecessors) agreed among themselves to keep a generic version of Niaspan off the market for more than eight years. The Plaintiffs have alleged that the defendants’ conduct caused consumers and drug benefit plans to pay more for Niaspan than they otherwise would have paid. Read more.

View more antitrust cases brought by Wexler Wallace.